How testosterone raises hematocrit
Testosterone stimulates red blood cell production through:
- Increased erythropoietin (EPO) production by kidney
- Direct effects on bone marrow erythroid progenitors
- Improved iron utilization
- Possibly suppressed hepcidin (which normally limits iron availability)
This is part of testosterone's normal physiology, men have higher hematocrit than women due to higher T. TRT amplifies this effect.
Typical magnitude
On standard TRT (100-200 mg testosterone cypionate weekly):
- Hematocrit typically rises 2-5 percentage points (e.g., 44% to 48%)
- Effect plateaus within 6-12 months
- Most patients land in upper normal range (47-50%)
- Subjective benefit: better oxygen delivery, often improved exercise capacity
When it becomes a problem
Erythrocytosis is hematocrit above 52% (women) or 54% (men). Risks of high hematocrit:
- Increased blood viscosity
- Increased clot risk (DVT, PE)
- Increased cardiovascular event risk theoretically
- Headaches, hypertension, plethora at extremes
About 5-15% of TRT patients develop erythrocytosis requiring intervention.
Risk amplifiers
Factors that increase hematocrit elevation risk:
- Sleep apnea (often undiagnosed), chronic intermittent hypoxia is a major hematocrit driver
- Smoking, chronic mild hypoxia
- Dehydration, concentrates blood
- Higher TRT doses, dose-dependent effect
- Less frequent injections, peak-trough variation amplifies erythropoiesis
- Higher altitude residence
Management strategies
- Dose reduction, most direct approach
- Switch to subq from IM, produces lower peaks and less hematocrit rise
- More frequent dosing, split weekly dose into 2x/week or daily for less peak-trough variation
- Therapeutic phlebotomy, donate blood (if eligible) or prescribed therapeutic phlebotomy
- Address sleep apnea if present, major underlying contributor
- Hydration, adequate water intake
- Stop smoking
Monitoring protocol
- Baseline CBC before starting TRT
- Recheck at 3, 6, 12 months
- Then every 6-12 months while stable
- More frequent if elevated or trending up
- OPTML's hormone panels include CBC routinely
The clinical pearl: Hematocrit elevation on TRT is manageable. Patients shouldn't fear it but should monitor it. The most common preventable contributor is undiagnosed sleep apnea, screen for it in patients with persistently elevated hematocrit.
Bottom line
Testosterone stimulates red blood cell production through erythropoietin and direct marrow effects. Most TRT patients see clinically irrelevant hematocrit rise. About 5-15% develop erythrocytosis requiring intervention. Management options exist; monitoring is standard. Sleep apnea is the most common amplifier worth identifying.